Johnson & Johnson discontinued two CAR-T programs in B-cell lymphoma, citing portfolio priorities and an evolving treatment landscape. The company said it is scrapping JNJ-9530 and JNJ-4496, programs that were in phase 1 and phase 1/2 development. J&J previously paid Cellular Biomedicine $245 million in 2023 for the CAR-T candidates, with later updates describing strong complete response rates at least in early cohorts for JNJ-4496. J&J will continue to support enrolled patients under trial protocols, the company said. The decision removes potential competitive pressure in the dual-targeting CAR-T space and reflects a broader industry pattern where sponsors prune assets when antibody-based and cell therapy options proliferate. For remaining CAR-T developers, the message is that differentiation by mechanism, durability expectations, and growth prospects must stay compelling even as approval density increases across lymphoma subtypes.